Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

This study will be evaluating safety and efficacy of the combination of lenvatinib and pembolizumab neoaadjuvant therapy prior to surgical resection of locally advanced renal cell carcinoma with IVC tumor thrombus.

Trial Details

NCT ID
NCT05319015
Phase
PHASE2
Sponsor
University of Texas Southwestern Medical Center
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Neoadjuvant Lenvatinib
  • Neoadjuvant Pembrolizumab
  • Radical nephrectomy, IVC thrombectomy, retroperitoneal lymph node dissection
  • Adjuvant Pembrolizumab
Locations (sample)
  • Dallas, Texas, United States|32.78306,-96.80667

Key Eligibility Criteria

  • Male/female participants who are at least 18 years of age on the day of signing informed consent
  • Have histologically confirmed cT3-4,N0-1,M0-1 (clinical stage III-IV) diagnosis of renal cell carcinoma (any subtype) with level II-IV inferior ven…
  • Level 1 tumor thrombus is either at the entry of renal vein or within the IVC \< 2 cm from the confluence of renal vein and IVC
  • Level II tumor thrombus extends within the IVC \> 2 cm above the confluence of renal vein and IVC, but still remains below the hepatic veins.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →